Receptors, Vascular Endothelial Growth Factor
"Receptors, Vascular Endothelial Growth Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of closely related RECEPTOR PROTEIN-TYROSINE KINASES that bind vascular endothelial growth factors. They share a cluster of seven extracellular IG-LIKE DOMAINS which are important for ligand binding. They are highly expressed in vascular endothelial cells and are critical for the physiological and pathological growth, development and maintenance of blood and lymphatic vessels.
Descriptor ID |
D040262
|
MeSH Number(s) |
D08.811.913.696.620.682.725.400.950 D12.776.543.750.630.750 D12.776.543.750.750.400.910
|
Concept/Terms |
Receptors, Vascular Endothelial Growth Factor- Receptors, Vascular Endothelial Growth Factor
- Receptor, Vascular Endothelial Cell Growth Factor
- Receptor, Vascular Permeability Factor
- VEGF Receptors
- Receptors, VEGF
- Vascular Endothelial Cell Growth Factor Receptor
- VPF Receptor
- Vascular Endothelial Growth Factor Receptor
- VEGF Receptor
- Vascular Permeability Factor Receptor
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Vascular Endothelial Growth Factor".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Vascular Endothelial Growth Factor".
This graph shows the total number of publications written about "Receptors, Vascular Endothelial Growth Factor" by people in this website by year, and whether "Receptors, Vascular Endothelial Growth Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 |
1998 | 0 | 1 | 1 |
1999 | 0 | 3 | 3 |
2000 | 0 | 3 | 3 |
2001 | 0 | 4 | 4 |
2002 | 0 | 6 | 6 |
2003 | 1 | 0 | 1 |
2004 | 5 | 5 | 10 |
2005 | 4 | 5 | 9 |
2006 | 2 | 4 | 6 |
2007 | 3 | 9 | 12 |
2008 | 6 | 7 | 13 |
2009 | 3 | 7 | 10 |
2010 | 2 | 4 | 6 |
2011 | 1 | 7 | 8 |
2012 | 2 | 3 | 5 |
2013 | 4 | 4 | 8 |
2014 | 3 | 5 | 8 |
2015 | 8 | 4 | 12 |
2016 | 5 | 3 | 8 |
2017 | 7 | 8 | 15 |
2018 | 2 | 4 | 6 |
2019 | 5 | 4 | 9 |
2020 | 6 | 1 | 7 |
2021 | 1 | 12 | 13 |
2022 | 1 | 9 | 10 |
2023 | 1 | 7 | 8 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Vascular Endothelial Growth Factor" by people in Profiles.
-
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors. Cancer Med. 2024 Feb; 13(3):e6877.
-
Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial. JAMA Ophthalmol. 2023 Dec 01; 141(12):1152-1160.
-
Longitudinal Quantitative Ultrawidefield Angiographic Features in Diabetic Retinopathy Treated with Aflibercept from the Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement Trial. Ophthalmol Retina. 2024 Feb; 8(2):116-125.
-
Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial. JAMA Ophthalmol. 2023 09 01; 141(9):834-842.
-
Effect of intravitreal anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration on renal function. Nephrol Dial Transplant. 2023 Jun 30; 38(7):1770-1772.
-
Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment. BMJ Open Ophthalmol. 2023 06; 8(1).
-
Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: 1-Year Outcomes. Invest Ophthalmol Vis Sci. 2023 Jun 01; 64(7):35.
-
Factors Linked to Injection Interval Extension in Eyes with Wet Age-Related Macular Degeneration Switched to Brolucizumab. Ophthalmology. 2023 08; 130(8):795-803.
-
INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PHARMACEUTICAL UTILIZATION AND FINANCIAL IMPACT IN A VALUE-BASED CARE PROGRAM. Retina. 2023 03 01; 43(3):506-513.
-
OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma. Cancer. 2022 10 01; 128(19):3516-3522.